Turn Therapeutics expands GX-03 Phase 2 atopic dermatitis study after interim analysis shows broader efficacy

Turn Therapeutics Inc.

TTRX

0.00

Turn Therapeutics set the final Stage 2 design for its adaptive Phase 2 trial of topical GX-03 in atopic dermatitis.
Interim analysis supported expanding enrollment to cover the full baseline EASI severity spectrum, starting at EASI ≥1.1.
Stage 2 targets 120-135 patients, stratified by baseline EASI, with 1:1 randomization within each stratum.
Week 4 showed the clearest treatment separation; Stage 2 adds Week 4 endpoints alongside Week 8 measures.
Enrollment expected to finish in the fourth quarter of 2026; runway projected through the third quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260707654155) on July 07, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.